Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Why Is Co-Diagnostics (CODX) Stock Down -12.81% Today?

Why Is Co-Diagnostics (CODX) Stock Down -12.81% Today?

Key Takeaways

  • CODX fell 12.81% to $0.1961 in early Tuesday trading, extending a brutal multi-week slide and printing a fresh 52-week low.
  • The move followed Monday's 13.03% drop and came with no new company release, filing, or analyst action during Tuesday's session.
  • The dominant overhang remains severe dilution: a 39.6 million-share resale registration, a convertible note with a 35% original issue discount, and shareholder approval of a reverse-split authorization.
  • Third-quarter results showed revenue of just $282,881 and a net loss of $6.31 million, with cash of only $714,803 at quarter-end.
  • Broader sentiment was defensive after the Nasdaq Composite fell 2.49% and the S&P 500 lost 1.92% on Monday in an AI-led tech selloff.
  • News Significance Score: 18/100 — No fresh catalyst; a familiar dilution and liquidity overhang met a move roughly twice the stock's normal daily swing.
  • Traders will watch whether the company proceeds with a reverse split, taps its remaining shelf capacity, and whether $0.19 holds as support.
  • Deeper fundamentals, including Price Targets, Earnings history, and a Forecast outlook, are available on dedicated pages for readers who want the full financial picture.
  • Readers can also explore Trending AI Robots to see which automated strategies are currently performing best across thousands of tickers.

Co-Diagnostics Extends Slide to a New 52-Week Low

Co-Diagnostics, Inc. (CODX) is a Salt Lake City-based molecular diagnostics company that designs, develops, and markets nucleic acid testing technology, including its Co-Dx PCR point-of-care platform and a portfolio of infectious-disease assays covering tuberculosis, influenza, RSV, and other pathogens. The company's platform tests are still awaiting regulatory clearance.

Shares were trading at $0.1961 shortly after Tuesday's open, down 12.81% from the prior session's close of $0.2249. The direction was unambiguously negative: the stock opened at $0.2054 and weakened through the morning to an intraday low of $0.19, a level below its previous 52-week trough of $0.2240. The decline follows a 13.03% drop on Monday and leaves the equity roughly 98% below where it traded a year ago. No verified news or fundamental catalyst found for the session itself; the selling appears to be a continuation of pressures already disclosed.

No Fresh Catalyst, Just a Persistent Dilution Overhang

Tuesday's weakness cannot be tied to a new press release, filing, analyst revision, or regulatory headline. Instead, the tape reflects an unresolved capital structure problem that investors have been repricing for weeks.

On November 4, the company registered up to 39,594,495 shares for resale on behalf of selling stockholders — a figure several times larger than its roughly 10.5 million shares outstanding — tied to an October secured convertible note carrying a 35% original issue discount, with ATM proceeds pledged to the lender. On November 13, shareholders approved an amendment authorizing one or more reverse stock splits at ratios from 1-for-2 up to a cumulative 1-for-750, along with warrant exercises for 3,404,724 shares at $1.56 and issuance of shares upon note conversion. Each of those items was public before Tuesday's move, but they collectively signal continued equity issuance and a likely bid-price compliance maneuver.

Third-Quarter Results Left Little Room for Error

The November 10 report set the tone for the current leg lower. Revenue of $282,881 beat modest expectations and operating expenses fell 12% year over year, but the company posted a net loss of $6.31 million, or $1.01 per share — a per-share loss several times the current share price. Cash and equivalents stood at just $714,803 at September 30, against meaningful ongoing operating cash burn, keeping going-concern language in focus. Management highlighted genuine pipeline progress, including a tuberculosis submission to India's CDSCO with roughly 97.3% sensitivity and a dual 510(k) and CLIA waiver filing for a Flu A/B and RSV test, but neither product is approved for sale, so no revenue inflection is imminent.

Market Context and Trading Activity

Volume in the first half-hour of trading totaled roughly 140,000 shares, a moderate pace rather than a capitulation event and well short of the 6.3 million shares that changed hands on November 10. The stock has averaged close to 2 million shares a day over three months, so participation looked ordinary for a name that has been heavily traded.

The broader backdrop was unsupportive. Monday's session saw the Nasdaq Composite fall 2.49% and the S&P 500 drop 1.92% as AI-linked technology shares sold off ahead of Nvidia's earnings, and small-cap, cash-burning healthcare names typically bear the brunt of that kind of risk reduction. Technically, the picture is decisively broken: the shares sit far below their 50-day and 200-day moving averages, with a relative strength index in the low 20s, and Tuesday's break below $0.2240 removed the last obvious support level.

News Significance Score

The score runs from 0 to 100, where 0 means no meaningful news and a move that is normal for the stock, and 100 means transformative news paired with an extreme, rare price move. Co-Diagnostics earns 18 out of 100.

The news component was weak: nothing new was published Tuesday, and the drivers behind the selling — dilution, thin liquidity, and the reverse-split authorization — are already known and were fully reflected in prior sessions. The price component was moderate at best. At 12.81%, Tuesday's decline was roughly 2.4 times the stock's average absolute daily move of about 5.4% over the last 60 sessions, and moves of equal or greater size occurred seven times in that window. Two modest components produce a low overall score.

What Comes Next for CODX

The next scheduled results are expected in late March 2027, leaving investors without a fundamental update for months. In the interim, attention centers on whether the board executes a reverse split to address the sub-$1 bid price, how quickly the resale registration is used, and whether the company can raise capital without further punitive terms. Regulatory decisions in India and at the FDA are the fundamental catalysts that could change the trajectory, but timelines are uncertain and approval is not guaranteed. Analyst coverage is thin, with a single Buy rating and a distant consensus target that reflects a far larger capital structure. Risks include continued cash burn, additional dilution, and potential Nasdaq listing-compliance pressure.

Trending AI Robots

Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in the curated Trending AI Robots section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so the featured list changes as market conditions shift. For readers navigating volatile micro-caps like this one, reviewing currently top-ranked automated strategies can add a useful, data-driven perspective before making any decision.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CODX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CODX in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 14, 2026

CODX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 34 cases where CODX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for CODX just turned positive on November 11, 2026. Looking at past instances where CODX's MACD turned positive, the stock continued to rise in 32 of 40 cases over the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CODX as a result. In 75 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

CODX moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CODX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CODX entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.141) is normal, around the industry mean (4.142). P/E Ratio (-0.010) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.171) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. CODX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CODX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -14%. POAS experienced the highest price growth at 172%, while LFWD experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -44%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -49%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 62
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of molecular diagnostics products and tests that represents a radical new advancement in the understanding of the molecular interactions of DNA

Industry MedicalNursingServices

Industry
Biotechnology
Address
2401 S. Foothill Drive
Phone
+1 801 438-1036
Employees
115
Web
https://www.codiagnostics.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.